Silexion Therapeutics Corp filed a Form 8-K on November 9, 2026, announcing a prospective 1-for-24 reverse share split of its ordinary shares, effective after the close of market on November 10, 2026.

Key Highlights

  • Reverse split ratio: 1-for-24, applied to all issued and outstanding, and authorized but unissued, ordinary shares.
  • Effective date: After the close of market on November 10, 2026; trading on a split-adjusted basis begins at market open on November 11, 2026.
  • Shareholder approval: Shareholders approved the reverse share split on October 26, 2026, according to the filing.
  • Par value change: The par value of ordinary shares will increase from $0.135 per share to $3.24 per share as a result of the split.
  • Ticker unchanged: The ordinary shares will continue to trade under the symbol "SLXN" on the Nasdaq Capital Market.
  • Fractional shares: No fractional shares will be issued; any fractional entitlements for DTC participant shareholders will be rounded up to the nearest whole number of shares.

Details of Silexion's 1-for-24 Reverse Share Split

According to the Form 8-K filed by Silexion Therapeutics Corp (NASDAQ:SLXN) on November 9, 2026, the company announced a 1-for-24 reverse share split covering all of its issued and outstanding, and authorized but unissued, ordinary shares. The filing noted that the action follows shareholder approval received on October 26, 2026, and is consistent with the company's previous reports on the matter. The reverse split is set to take effect after the close of market on November 10, 2026, with split-adjusted trading commencing on the Nasdaq Capital Market at the open of market on November 11, 2026.

The filing disclosed that the reverse share split will be effected automatically, "without any action required on the part of the Company's shareholders." A corresponding increase in par value is described, moving from $0.135 per share to $3.24 per share. The company also disclosed that no fractional shares will be issued as a result of the split, and that any fractional share totals to which shareholders who are DTC participants become entitled will be rounded up to the nearest whole number of shares.

The company's ordinary shares are registered on The Nasdaq Stock Market LLC under trading symbol "SLXN," and the filing states the ticker symbol will remain "SLXN" following the reverse split. Warrants exercisable for ordinary shares, trading under the symbol "SLXNW," are also listed on The Nasdaq Stock Market LLC with an exercise price of $15,525.00 per share, as stated on the filing's cover page. The press release announcing the reverse share split is attached as Exhibit 99.1 to the report.

What Was Disclosed

Silexion Therapeutics Corp disclosed a 1-for-24 reverse share split of all ordinary shares, effective November 10, 2026, with split-adjusted trading beginning November 11, 2026. Par value increases from $0.135 to $3.24 per share, and the ticker symbol "SLXN" remains unchanged.